Abstract
Liver is the common site for metastases from colorectal cancer. The 5-year overall survival rate of patients following radical operations is 25%. Surgery can be carried out in only 10-15% of the patients, yet it remains the potential curative treatment for resectable lesions. For the unresectable cancers, only chemotherapy is recommended. New drugs such as Irinotecan prolongs the overall survival of patients affected by advanced disease. In patients with unresectable metastases at diagnosis, pre-surgical treatment with Oxaliplatin leads to reduction of the lesions, allowing resection in 16% of cases. Chemotherapy may be delivered directly into the liver via the hepatic artery. No, clinical trials, to date, have shown convincing survival results in patients treated with this procedure. Combined hepatic artery and systemic treatment may provide a new strategy as adjuvant therapy for patients undergoing resections.
| Original language | English |
|---|---|
| Pages (from-to) | 438-444 |
| Number of pages | 7 |
| Journal | Digestive and Liver Disease |
| Volume | 33 |
| Issue number | 5 |
| Publication status | Published - 2001 |
Fingerprint
Keywords
- Colorectal cancer
- Liver metastases
- Local chemotherapy
- Systemic chemotherapy
ASJC Scopus subject areas
- Gastroenterology
Cite this
Treatment of liver metastases from colorectal cancer : What is the best approach today? / Biasco, G.; Gallerani, E.
In: Digestive and Liver Disease, Vol. 33, No. 5, 2001, p. 438-444.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Treatment of liver metastases from colorectal cancer
T2 - What is the best approach today?
AU - Biasco, G.
AU - Gallerani, E.
PY - 2001
Y1 - 2001
N2 - Liver is the common site for metastases from colorectal cancer. The 5-year overall survival rate of patients following radical operations is 25%. Surgery can be carried out in only 10-15% of the patients, yet it remains the potential curative treatment for resectable lesions. For the unresectable cancers, only chemotherapy is recommended. New drugs such as Irinotecan prolongs the overall survival of patients affected by advanced disease. In patients with unresectable metastases at diagnosis, pre-surgical treatment with Oxaliplatin leads to reduction of the lesions, allowing resection in 16% of cases. Chemotherapy may be delivered directly into the liver via the hepatic artery. No, clinical trials, to date, have shown convincing survival results in patients treated with this procedure. Combined hepatic artery and systemic treatment may provide a new strategy as adjuvant therapy for patients undergoing resections.
AB - Liver is the common site for metastases from colorectal cancer. The 5-year overall survival rate of patients following radical operations is 25%. Surgery can be carried out in only 10-15% of the patients, yet it remains the potential curative treatment for resectable lesions. For the unresectable cancers, only chemotherapy is recommended. New drugs such as Irinotecan prolongs the overall survival of patients affected by advanced disease. In patients with unresectable metastases at diagnosis, pre-surgical treatment with Oxaliplatin leads to reduction of the lesions, allowing resection in 16% of cases. Chemotherapy may be delivered directly into the liver via the hepatic artery. No, clinical trials, to date, have shown convincing survival results in patients treated with this procedure. Combined hepatic artery and systemic treatment may provide a new strategy as adjuvant therapy for patients undergoing resections.
KW - Colorectal cancer
KW - Liver metastases
KW - Local chemotherapy
KW - Systemic chemotherapy
UR - http://www.scopus.com/inward/record.url?scp=0034912691&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034912691&partnerID=8YFLogxK
M3 - Article
VL - 33
SP - 438
EP - 444
JO - Digestive and Liver Disease
JF - Digestive and Liver Disease
SN - 1590-8658
IS - 5
ER -